Federal grants to Hillhurst Biopharmaceuticals, Inc.
Hillhurst Biopharmaceuticals, Inc. in Glendale, California received $9.8 million in federal grants from fiscal 2021 to 2025, across 10 awards. Its largest program was Cardiovascular Diseases Research, with $3.4 million. In fiscal 2025 it was awarded $1.8 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$9.8 million
- Awards10
- Awarded in FY 2025$1.8 million
- Largest award$3.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 4 | $927,639 |
| FY 2022 | 3 | $2.6 million |
| FY 2023 | 2 | $1.3 million |
| FY 2024 | 4 | $3.1 million |
| FY 2025 | 2 | $1.8 million |
Programs that fund Hillhurst Biopharmaceuticals, Inc.
| Program | Awards | Amount |
|---|---|---|
| Cardiovascular Diseases Research | 3 | $3.4 million |
| Drug Use and Addiction Research Programs | 2 | $2.8 million |
| Vision Research | 2 | $2.2 million |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 1 | $633,912 |
| Allergy and Infectious Diseases Research | 1 | $599,788 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 1 | $75,058 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 10 | $9.8 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| HBI-002 to prevent vaso-occlusive crises in sickle cell disease | Cardiovascular Diseases Research | June 17, 2021 | $3.0 million |
| Oral N2O therapy in treating acute vaso-occlusive pain in sickle cell disease - the goal of the proposed project is to evaluate the potential of and develop HBI-201, a novel oral formulation of nitrous oxide (N2O), that enables the home use of N2O to treat pain associated with vaso-occlusive crises | Drug Use and Addiction Research Programs | August 5, 2022 | $2.1 million |
| HBI-002 to treat diabetic retinopathy - project summary diabetic retinopathy (DR) is a neurovascular complication of diabetes mellitus and the leading cause of blindness in working age adults and elderly, affecting approximately 4.2 million diabetes patients in the us. There is an urgent need for th | Vision Research | September 12, 2024 | $1.9 million |
| Oral N2O therapy in treating acute vaso-occlusive pain in sickle cell disease - the goal of the proposed project is to evaluate the potential of and develop HBI-201, a novel oral formulation of nitrous oxide (N2O), that enables the home use of N2O to treat pain associated with vaso-occlusive crises | Drug Use and Addiction Research Programs | September 9, 2024 | $728,111 |
| HBI-002 to treat parkinson?s disease - project summary the goal of the proposed project is to evaluate the potential of HBI-002, a novel oral formulation of carbon monoxide (CO), as a neuroprotective agent in parkinson’s disease (PD). A growing body of research suggests that low doses of co - and th | Extramural Research Programs in the Neurosciences and Neurological Disorders | September 17, 2021 | $633,912 |
| Low dose oral carbon monoxide therapeutic for virus-induced lung injury - project summary there is an urgent need for the development of new approaches to treat patients suffering from pulmonary injury from viral infections, as demonstrated by the severe impact of COVID-19, which is a global pandemi | Allergy and Infectious Diseases Research | August 11, 2022 | $599,788 |
| HBI-002 for cystic fibrosis - project summary there is an urgent need for the development of new approaches to treat patients suffering from cystic fibrosis (CF). Cf results in a poor quality of life and a median life expectancy in the U.S. Of only ~46 years of age, despite a number of available dru | Cardiovascular Diseases Research | April 10, 2024 | $299,975 |
| HBI-002 to treat diabetic retinopathy - project summary diabetic retinopathy (DR) is a neurovascular complication of diabetes mellitus and the leading cause of blindness in working age adults and elderly, affecting approximately 4.2 million diabetes patients in the us, of which 655,000 have vision-t | Vision Research | August 18, 2021 | $299,899 |
| HBI-002 to prevent anthracycline-related cardiotoxicity | Cardiovascular Diseases Research | April 8, 2021 | $99,524 |
| HBI-002 to treat ulcerative colitis | Diabetes, Digestive, and Kidney Diseases Extramural Research | April 28, 2021 | $75,058 |
Questions people ask
How much federal grant money does Hillhurst Biopharmaceuticals, Inc. get?
$9.8 million in 10 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Hillhurst Biopharmaceuticals, Inc. the most?
The Department of Health and Human Services, with $9.8 million in 10 awards.
What is Hillhurst Biopharmaceuticals, Inc.'s largest federal grant?
$3.0 million under Cardiovascular Diseases Research, with its first action in the period on June 17, 2021. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Hillhurst Biopharmaceuticals, Inc.?
Its largest are Cardiovascular Diseases Research, Drug Use and Addiction Research Programs and Vision Research.
Other grant recipients in Glendale
- Glendale Community College District
- City of Glendale
- Comprehensive Community Health Centers Inc
- All for Health, Health for All, Inc.
- Interagency Communications Interoperability System Jpa
- YWCA of Glendale and Pasadena
- Southwest College of Medical-Dental Assistants & Practical Nurses
- Element 16 Technologies Inc
Largest federal grant recipients in California · Federal grants in California